(Q44089196)

29 November 2017

title

Short treatment durations for acute bacterial rhinosinusitis: Five days of gemifloxacin versus 7 days of gemifloxacin (English)

1 reference

29 November 2017

1 reference

Berrylin J Ferguson

1

1 reference

29 November 2017

Jack Anon

2

1 reference

29 November 2017

Michael D Poole

3

1 reference

29 November 2017

Kim Hendrick

4

1 reference

29 November 2017

Martyn Gilson

5

1 reference

29 November 2017

Elyse G Seltzer

6

1 reference

29 November 2017

Gemifloxacin 186 Study Group

7

1 reference

29 November 2017

publication date

1 July 2002

1 reference

Otolaryngology—Head and Neck Surgery

29 November 2017

published in

1 reference

29 November 2017

volume

127

1 reference

29 November 2017

issue

1

1 reference

29 November 2017

page(s)

1-6

1 reference

First place--resident basic science award 1999. Effects of leukotriene and cyclo-oxygenase inhibition on adaptive bone remodeling in the middle ear.

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1067%2FMHN.2002.126593

The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: a fifteen-year experience at the University of Virginia and review of other selected studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1067%2FMHN.2002.126593

The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1067%2FMHN.2002.126593

21 January 2018

1 reference

https://api.crossref.org/works/10.1067%2FMHN.2002.126593

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1067%2FMHN.2002.126593

In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1067%2FMHN.2002.126593

Trends in antimicrobial drug prescribing among office-based physicians in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1067%2FMHN.2002.126593

Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1067%2FMHN.2002.126593

Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1067%2FMHN.2002.126593

Comparative in vitro activity of gemifloxacin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1067%2FMHN.2002.126593

Approaches to limiting emergence of antimicrobial resistance in bacteria in human populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1067%2FMHN.2002.126593

Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1067%2FMHN.2002.126593

21 January 2018

1 reference

https://api.crossref.org/works/10.1067%2FMHN.2002.126593

Comparison of the effectiveness of levofloxacin and amoxicillin-clavulanate for the treatment of acute sinusitis in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1067%2FMHN.2002.126593

Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1067%2FMHN.2002.126593

21 January 2018

Toxicity of quinolones

1 reference

https://api.crossref.org/works/10.1067%2FMHN.2002.126593

21 January 2018

Identifiers

DOI

10.1067/MHN.2002.126593

1 reference

29 November 2017

1 reference